Cargando…

OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma

Introduction: Parathyroidectomy is the standard of care for the treatment of primary hyperparathyroidism (PHP). Patients who are not surgical candidates have limited options of treatment. Percutaneous ethanol injection (PEI) for the treatment of parathyroid adenoma was first introduced in the 1980s....

Descripción completa

Detalles Bibliográficos
Autores principales: Nakhle, Samer, hoefler, Edward, Izkhkov, Neriy, Ayutyanont, Napatkamon, Akhondi, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554800/
http://dx.doi.org/10.1210/js.2019-OR30-2
_version_ 1783425021983588352
author Nakhle, Samer
hoefler, Edward
Izkhkov, Neriy
Ayutyanont, Napatkamon
Akhondi, Hossein
author_facet Nakhle, Samer
hoefler, Edward
Izkhkov, Neriy
Ayutyanont, Napatkamon
Akhondi, Hossein
author_sort Nakhle, Samer
collection PubMed
description Introduction: Parathyroidectomy is the standard of care for the treatment of primary hyperparathyroidism (PHP). Patients who are not surgical candidates have limited options of treatment. Percutaneous ethanol injection (PEI) for the treatment of parathyroid adenoma was first introduced in the 1980s. Main safety and efficacy data about PEI of parathyroid adenoma comes from the mayo clinic review publication of the treatment of recurrent primary hyperparathyroidism in patient with MEN1. There is no large review of the treatment of PHP. In our practice, we localize the parathyroid adenoma with ultrasound in preparation for surgery. In addition, non-surgical patients who meet the criteria for treatment of hyperparathyroidism get offered the PEI as an option of treatment. All patients who were treated with PEI had FNA from the parathyroid adenoma and PTH level was measured on the aspirate to confirm the diagnosis. Study design: This is a retrospective longitudinal cohort study of calcium and PTH level in patient with PHP after PEI treatment. All patients with PHP who received PEI treatment between 2013 and 2017 electronic chart was reviewed and data was collected about calcium, PTH level before treatment and after treatment up to one year, also side effect and complication of the procedure was collected. Patient who we do not have the 6 months data we assumed treatment failure Result: Baseline characteristic 60 patients, age 34 to 95, 49 female and 11 male, PTH average 136, calcium average 11.2 Normal calcium was achieved in 39 patients (65%) at 1 week after the PEI and 36 patients (58%) at 6 months, also at 6 months the 26 patients who continued to have elevated calcium 17 of them (65%) had improvement in calcium level after the treatment and it was below 11.2. At one year we did not have lab result for all patients, out of the 36 patients who had normal calcium at 6 months we have the result of 29 patients and they continue to have normal calcium Complications from the procedure: pain in the injection site for a few minutes after injection, 4 patients (6%) had hoarseness that resolved in two weeks in 3 patients and one patient had hoarseness that persisted after one year Conclusion: This is the largest cohort of PHP patients treated with PEI and it showed 58% normalization of calcium after treatment. The main significant complication was recurrent nerve injury which was temporary in most cases
format Online
Article
Text
id pubmed-6554800
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65548002019-06-13 OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma Nakhle, Samer hoefler, Edward Izkhkov, Neriy Ayutyanont, Napatkamon Akhondi, Hossein J Endocr Soc Bone and Mineral Metabolism Introduction: Parathyroidectomy is the standard of care for the treatment of primary hyperparathyroidism (PHP). Patients who are not surgical candidates have limited options of treatment. Percutaneous ethanol injection (PEI) for the treatment of parathyroid adenoma was first introduced in the 1980s. Main safety and efficacy data about PEI of parathyroid adenoma comes from the mayo clinic review publication of the treatment of recurrent primary hyperparathyroidism in patient with MEN1. There is no large review of the treatment of PHP. In our practice, we localize the parathyroid adenoma with ultrasound in preparation for surgery. In addition, non-surgical patients who meet the criteria for treatment of hyperparathyroidism get offered the PEI as an option of treatment. All patients who were treated with PEI had FNA from the parathyroid adenoma and PTH level was measured on the aspirate to confirm the diagnosis. Study design: This is a retrospective longitudinal cohort study of calcium and PTH level in patient with PHP after PEI treatment. All patients with PHP who received PEI treatment between 2013 and 2017 electronic chart was reviewed and data was collected about calcium, PTH level before treatment and after treatment up to one year, also side effect and complication of the procedure was collected. Patient who we do not have the 6 months data we assumed treatment failure Result: Baseline characteristic 60 patients, age 34 to 95, 49 female and 11 male, PTH average 136, calcium average 11.2 Normal calcium was achieved in 39 patients (65%) at 1 week after the PEI and 36 patients (58%) at 6 months, also at 6 months the 26 patients who continued to have elevated calcium 17 of them (65%) had improvement in calcium level after the treatment and it was below 11.2. At one year we did not have lab result for all patients, out of the 36 patients who had normal calcium at 6 months we have the result of 29 patients and they continue to have normal calcium Complications from the procedure: pain in the injection site for a few minutes after injection, 4 patients (6%) had hoarseness that resolved in two weeks in 3 patients and one patient had hoarseness that persisted after one year Conclusion: This is the largest cohort of PHP patients treated with PEI and it showed 58% normalization of calcium after treatment. The main significant complication was recurrent nerve injury which was temporary in most cases Endocrine Society 2019-04-30 /pmc/articles/PMC6554800/ http://dx.doi.org/10.1210/js.2019-OR30-2 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Bone and Mineral Metabolism
Nakhle, Samer
hoefler, Edward
Izkhkov, Neriy
Ayutyanont, Napatkamon
Akhondi, Hossein
OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
title OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
title_full OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
title_fullStr OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
title_full_unstemmed OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
title_short OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
title_sort or30-2 efficacy and safety of percutaneous ethanol ablation of parathyroid adenoma
topic Bone and Mineral Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554800/
http://dx.doi.org/10.1210/js.2019-OR30-2
work_keys_str_mv AT nakhlesamer or302efficacyandsafetyofpercutaneousethanolablationofparathyroidadenoma
AT hoefleredward or302efficacyandsafetyofpercutaneousethanolablationofparathyroidadenoma
AT izkhkovneriy or302efficacyandsafetyofpercutaneousethanolablationofparathyroidadenoma
AT ayutyanontnapatkamon or302efficacyandsafetyofpercutaneousethanolablationofparathyroidadenoma
AT akhondihossein or302efficacyandsafetyofpercutaneousethanolablationofparathyroidadenoma